Skip to content
Original
mp.weixin.qq.com·· 5 hours agoScore93

Roche divarasib cuts risk of death 44% in Krascendo 1 Phase 3 KRAS G12C advanced NSCLC study

In brief

Roche announced Phase 3 Krascendo 1 results for divarasib, showing a 44% reduction in the risk of death compared with existing KRAS G12C-targeted therapies in previously treated advanced or metastatic non-small cell lung cancer.

Source: mp.weixin.qq.com · mp.weixin.qq.com

#Clinical readout#Oncology#Roche
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.